Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Nissen, S. Nicholls, K. Wolski, R. Nesto, S. Kupfer, Alfonso Perez, H. Jure, Robert Larochellière, C. Staniloae, K. Mavromatis, J. Saw, Bo Hu, A. Lincoff, E. Tuzcu, for Investigators (2008)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.JAMA, 299 13
S. Nissen, E. Tuzcu, P. Schoenhagen, B. Brown, Peter Ganz, Robert Vogel, T. Crowe, Gail Howard, Christopher Cooper, Bruce Brodie, C. Grines, Anthony DeMaria (2004)
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA, 291 9
A. Khera, M. Cuchel, M. Llera-Moya, Amrith Rodrigues, Megan Burke, K. Jafri, B. French, J. Phillips, Megan Mucksavage, R. Wilensky, E. Mohler, G. Rothblat, D. Rader (2011)
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.The New England journal of medicine, 364 2
S. Nissen, S. Nicholls, I. Sipahi, P. Libby, J. Raichlen, C. Ballantyne, J. Davignon, R. Erbel, J. Tardif, P. Schoenhagen, T. Crowe (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA, 295 13
S. Nissen, E. Tuzcu, P. Libby, P. Thompson, M. Ghali, D. Garza, L. Berman, H. Shi, Ethel Buebendorf, E. Topol, for Investigators (2004)
Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled TrialJAMA, 292
S. Nicholls, A. Gordon, J. Johansson, K. Wolski, C. Ballantyne, J. Kastelein, Allen Taylor, Marilyn Borgman, S. Nissen (2011)
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.Journal of the American College of Cardiology, 57 9
S. Mora, J. Otvos, N. Rifai, R. Rosenson, J. Buring, P. Ridker (2009)
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in WomenCirculation, 119
T. Gordon, W. Castelli, M. Hjortland, W. Kannel, T. Dawber (1977)
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.The American journal of medicine, 62 5
P. Toth (2012)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyYearbook of Medicine, 2012
T. Dawber (2014)
The Framingham Study
P. Schoenhagen, Shelly Sapp, E. Tuzcu, W. Magyar, Jennifer Popovich, M. Boumitri, D. Vince, T. Crowe, S. Nissen (2003)
Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, 16 3
D. Cutler, C. Lehman (2007)
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
J. Tardif, J. Grégoire, P. L'allier, R. Ibrahim, J. Lésperance, T. Heinonen, S. Kouz, C. Berry, R. Basser, M. Lavoie, M. Guertin, J. Rodés‐Cabau (2007)
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.JAMA, 297 15
P. Libby (2005)
The forgotten majority: unfinished business in cardiovascular risk reduction.Journal of the American College of Cardiology, 46 7
S. Nissen, S. Nicholls, K. Wolski, J. Rodés‐Cabau, C. Cannon, J. Deanfield, J. Despres, J. Kastelein, S. Steinhubl, S. Kapadia, M. Yasin, W. Rużyłło, C. Gaudin, Bernard Job, Bo Hu, Deepak Bhatt, A. Lincoff, E. Tuzcu (2008)
Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.JAMA, 299 13
G. Schwartz, A. Olsson, M. Abt, C. Ballantyne, P. Barter, J. Brumm, B. Chaitman, I. Holme, D. Kallend, Lawrence Leiter, E. Leitersdorf, J. McMurray, H. Mundl, S. Nicholls, P. Shah, J. Tardif, R. Wright (2012)
Effects of dalcetrapib in patients with a recent acute coronary syndrome.The New England journal of medicine, 367 22
A. Otocka-Kmiecik, D. Mikhailidis, S. Nicholls, M. Davidson, J. Rysz, M. Banach (2012)
Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Progress in lipid research, 51 4
M Banach, M Rizzo, PP Toth (2015)
Statin intolerance—an attempt at a unified definition. Position paper from an International Lipid Expert PanelArch Med Sci AMS., 11
M. Landray, R. Haynes, J. Hopewell, S. Parish, Theingi Aung, J. Tomson, K. Wallendszus, M. Craig, Lixin Jiang, R. Collins, J. Armitage (2014)
Effects of extended-release niacin with laropiprant in high-risk patients.The New England journal of medicine, 371 3
S. Nicholls, A. Gordon, Jan Johannson, C. Ballantyne, P. Barter, H. Brewer, J. Kastelein, N. Wong, Marilyn Borgman, S. Nissen (2012)
ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE StudiesCardiovascular Drugs and Therapy, 26
J. Badimón, L. Badimón, A. Gálvez, R. Dische, Fuster (1989)
High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits.Laboratory investigation; a journal of technical methods and pathology, 60 3
R. Waksman, R. Torguson, K. Kent, A. Pichard, W. Suddath, L. Satler, Brenda Martin, T. Perlman, Jo-Ann Maltais, N. Weissman, Peter Fitzgerald, H. Brewer (2010)
A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome.Journal of the American College of Cardiology, 55 24
S. Nissen, T. Tsunoda, E. Tuzcu, P. Schoenhagen, C. Cooper, M. Yasin, G. Eaton, M. Lauer, W. Sheldon, C. Grines, S. Halpern, T. Crowe, J. Blankenship, R. Kerensky (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.JAMA, 290 17
R. Puri, S. Nissen, C. Ballantyne, P. Barter, M. Chapman, R. Erbel, P. Libby, J. Raichlen, J. John, K. Wolski, K. Uno, Y. Kataoka, S. Nicholls (2013)
Factors underlying regression of coronary atheroma with potent statin therapy.European heart journal, 34 24
T. Bhattacharyya, S. Nicholls, E. Topol, Renliang Zhang, Xia Yang, D. Schmitt, Xiaoming Fu, M. Shao, D. Brennan, S. Ellis, M. Brennan, H. Allayee, A. Lusis, S. Hazen (2008)
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.JAMA, 299 11
S. Nicholls, A. Hsu, K. Wolski, Bo Hu, O. Bayturan, A. Lavoie, K. Uno, E. Tuzcu, S. Nissen (2010)
Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome.Journal of the American College of Cardiology, 55 21
S. Nissen, E. Tuzcu, H. Brewer, I. Sipahi, Stephen Nicholls, Peter Ganz, P. Schoenhagen, David Waters, Carl Pepine, T. Crowe, M. Davidson, John Deanfield, Lisa Wisniewski, James Hanyok, Laurent Kassalow (2006)
Effect of ACAT inhibition on the progression of coronary atherosclerosis.The New England journal of medicine, 354 12
Stephen Nicholls, C. Ballantyne, P. Barter, M. Chapman, Raimund Erbel, P. Libby, J. Raichlen, K. Uno, Marilyn Borgman, K. Wolski, S. Nissen (2011)
Effect of two intensive statin regimens on progression of coronary disease.The New England journal of medicine, 365 22
M. Banach, M. Rizzo, P. Toth, M. Farnier, Michael Davidson, Khalid Al-Rasadi, W. Aronow, V. Athyros, D. Djuric, M. Ezhov, R. Greenfield, G. Hovingh, K. Kostner, C. Serban, D. Lighezan, Z. Fras, P. Moriarty, P. Muntner, A. Goudev, R. Češka, S. Nicholls, M. Broncel, D. Nikolić, D. Pella, R. Puri, J. Rysz, N. Wong, L. Bajnok, S. Jones, K. Ray, D. Mikhailidis (2015)
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert PanelExpert Opinion on Drug Safety, 14
D. Bailey, R. Jahagirdar, A. Gordon, A. Hafiane, S. Campbell, S. Chatur, G. Wagner, H. Hansen, Fabrizio Chiacchia, J. Johansson, L. Krimbou, N. Wong, J. Genest (2010)
RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo.Journal of the American College of Cardiology, 55 23
Am J Cardiovasc Drugs (2016) 16:55–65 DOI 10.1007/s40256-015-0146-z OR IGINAL RESEARCH ARTIC L E Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial 1 2 2 3 • • • • Stephen J. Nicholls Rishi Puri Kathy Wolski Christie M. Ballantyne 4 5 6 2 • • • • Philip J. Barter H. Bryan Brewer John J. P. Kastelein Bo Hu 2 1 7 8 • • • • Kiyoko Uno Yu Kataoka Jean-Paul R. Herrman Bela Merkely 2 2 Marilyn Borgman Steven E. Nissen Published online: 18 September 2015 Springer International Publishing Switzerland 2015 Abstract baseline) and 12.8 % with RVX-208 (P\ 0.001 compared Background Bromodomain and extra-terminal (BET) with baseline), between groups P = 0.18. HDL-C increased proteins regulate transcription of lipoprotein and inflam- by 9.1 % with placebo (P\ 0.001 compared with baseline) matory factors implicated in atherosclerosis. The impact of and 11.1 % with RVX-208 (P\ 0.001 compared with BET inhibition on atherosclerosis progression is unknown. baseline), between groups P = 0.24. Low-density lipoprotein Methods ASSURE was a double-blind, randomized, cholesterol (LDL-C) decreased by 17.9 % with placebo multicenter trial in which
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 18, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.